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a b s t r a c t
The acetylenic tricyclic bis(cyanoenone) TBE-31 is a highly potent cysteine targeting compound with a
reversible covalent mode of action; its best-characterized target being Kelch-like ECH-associated
protein-1 (Keap1), the cellular sensor for oxidants and electrophiles. TBE-31 reacts with cysteines of
Keap1, impairing its ability to target nuclear factor-erythroid 2 p45-related factor 2 (Nrf2) for degrada-
tion. Consequently, Nrf2 accumulates and orchestrates cytoprotective gene expression. In this study we
investigated the pharmacokinetic and pharmacodynamic properties of TBE-31 in C57BL/6 mice. After a
single oral dose of 10 mmol/kg (~200 nmol/animal), the concentration of TBE-31 in blood exhibited two
peaks, at 22.3 nM and at 15.5 nM, 40 min and 4 h after dosing, respectively, as determined by a quan-
titative stable isotope dilution LC-MS/MS method. The AUC0e24h was 195.5 h/nmol/l, the terminal
elimination half-life was 10.2 h, and the kel was 0.068 h1. To assess the pharmacodynamics of Nrf2
activation by TBE-31, we determined the enzyme activity of its prototypic target, NAD(P)H:quinone
oxidoreductase 1 (NQO1) and found it elevated by 2.4- and 1.5-fold in liver and heart, respectively.
Continuous feeding for 18 days with diet delivering the same daily doses of TBE-31 under conditions of
concurrent treatment with the immunosuppressive agent azathioprine had a similar effect on Nrf2
activation without any indications of toxicity. Together with previous reports showing the cytoprotective
effects of TBE-31 in animal models of carcinogenesis, our results demonstrate the high potency, efﬁcacy
and suitability for chronic administration of cysteine targeting reversible covalent drugs.
© 2015 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
1. Introduction
Electrophilic oleﬁns react readily with nucleophilic cysteine
sulfhydryl groups in a reversible manner. The presence of an elec-
tron withdrawing nitrile group adjacent to an oleﬁn increases the
reactivity, and furthermore, enhances the reversibility of the reac-
tion [1]. The ability of small molecules to bind their protein targets
covalently but reversibly is gaining an increasing interest in drug
development as such compounds provide sustained covalent
inhibition without accumulating permanently modiﬁed (and
potentially cytotoxic) proteins. The concept of designing reversible
covalent inhibitors has been recently employed to obtain non-
catalytic cysteine targeting drug candidates with high ligand efﬁ-
ciency and selectivity for the MSK/RSK-family protein kinases [2]. A
reversible covalent mode of action combines the desirable features
of both irreversible covalent agents (such as high potency and long-
lasting activity) as well as reversible non-covalent drugs (such as
lack of permanent target modiﬁcation). One example of a cysteine
targeting compound with a reversible covalent mode of action is
the acetylenic tricyclic bis(cyanoenone) (±)-(4bS,8aR,10aS)-10a-
ethynyl-4b,8,8-trimethyl-3,7-dioxo-3.4b,7,8,8a,9,10, 10a-octahy-
drophenanthrene-2,6-dicarbonitrile (TBE-31, Fig. 1A).
TBE-31 has two doubly activated Michael acceptors that render
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this compound highly reactive with sulfhydryl groups (Fig. 1A). The
best-characterized intracellular target of TBE-31 is Kelch-like ECH-
associated protein-1 (Keap1), the protein sensor for oxidants and
electrophiles [3]. Under homeostatic conditions, Keap1 binds
transcription factor nuclear factor-erythroid 2 p45-related factor 2
(Nrf2) [4,5] and functions as a substrate adapter for the Cul3-
mediated ubiquitination and proteasomal degradation of Nrf2
[6e8] by use of a highly efﬁcient cyclic mechanism [9]. Conse-
quently, the half-live of Nrf2 is very short (~10e20 min) [10].
Pharmacological activators of Nrf2 react with speciﬁc cysteine
residues of Keap1 [3,11e13], disrupting the cycle of Nrf2 degrada-
tion and leading to Nrf2 accumulation, nuclear translocation and
enhanced target gene expression. The battery of Nrf2 transcrip-
tional targets comprises genes encoding proteins with versatile
cytoprotective functions, including antioxidant, anti-inﬂammatory
and metabolic enzymes [14].
TBE-31 is one of the most potent Nrf2 activators known to date.
In vitro, this acetylenic tricyclic bis(cyanoenone) binds reversibly to
sulfhydryl groups such as those present in the reduced form of
Cleland's reagent (dithiothreitol, DTT) [15,16] and to cysteine sen-
sors of recombinant Keap1 [16,17]. In cells, at sub-to low nanomolar
concentrations, TBE-31 induces Nrf2 transcriptional targets, and
inhibits pro-inﬂammatory responses, such as the transcriptional
upregulation of inducible nitric oxide synthase (iNOS) mediated by
lipopolysaccharide or interferon-g (IFN-g). In vivo, small (nmol)
doses of TBE-31 robustly induce Nrf2-dependent cytoprotective
responses [16,18] and protect animals against hepatocarcinogenesis
induced by aﬂatoxin [15], as well as against cutaneous carcino-
genesis mediated by solar-simulated ultraviolet radiation [19]. The
aims of the present study were to: (i) deﬁne the pharmacokinetics
of a single dose of orally administered TBE-31 in mice, (ii) evaluate
the pharmacodynamics of Nrf2 activation by TBE-31 when
administered either at a single dose or chronically, and (iii) to
evaluate the safety of chronic administration of TBE-31 as exemplar
of a highly potent Nrf2 activator with a reversible covalent mode of
action.
2. Materials and methods
2.1. Materials
All reagentswere of the highest purity available, purchased from
common commercial suppliers. (±)-TBE-31 and a stable isotope
labeled (±)-[13C215N2]-TBE-31were synthesized as described [17,20].
2.2. Animals and treatments
The animal experiments were performed in accordancewith the
regulations described in the UK Animals (Scientiﬁc Procedures) Act
1986, and were in strict compliance with institutional guidelines.
C57BL/6 mice were bred in our facility and maintained on a 12-h
light/12-h dark cycle, 35% humidity with free access to water and
pelleted RM1 diet (SDS Ltd., Witham, Essex, UK). All experimental
animals were female, 6e12 weeks of age, uniformly distributed
between the treated and the control groups.
For single dose experiments, TBE-31 [10 mmol/kg, or ~200 nmol/
mouse (n ¼ 3), dissolved in 2% DMSO (v/v) in corn oil] was
administered by oral gavage. Control mice received an equivalent
volume of 2% DMSO (v/v) in corn oil. Blood (10 ml) was drawn from
the tail vein at 10, 20, 40, 60 min post-dosing, and subsequently at
2, 4, 6, 8, and 24 h. The blood was collected in heparin-containing
tubes and stored at e 80 C until analysis.
For continuous dietary administration of TBE-31, the compound
was mixed with powdered RM1 diet (27.6 mg of TBE-31 per kg of
food). The estimated dose of TBE-31 delivered by this diet was
~10 mmol/kg, or ~200 nmol/mouse (n ¼ 6) per day. The TBE-31 diet
was stored at 4 C, and the feeders were reﬁlled daily over the
course of the experiment (18 days). Control mice (n ¼ 6) were fed
RM1 diet that was stored and delivered under identical conditions.
The animals in both groups were receiving azathioprine (10 mg/kg)
in the drinking water. Body weights were recorded twice aweek. At
termination of the experiments, the animals were euthanized by
CO2 asphyxiation, and immediately exsanguinated by cardiac
puncture. Blood was drawn in EDTA-containing tubes, plasma was
isolated by centrifugation, and stored at e 80 C until analysis.
Livers, hearts, skin, kidneys, and stomachs were harvested, imme-
diately frozen in liquid N2, and stored at e 80 C.
2.3. Determination of blood levels of TBE-31
The blood levels of TBE-31 were determined using a stable
isotope dilution LC-MS method. Brieﬂy, 10 ml whole blood was
extracted in 0.5 ml acetonitrile using 500 pmol [13C215N2]-TBE-31
(10 ml of a 50 mM solution) as an internal standard. The sample was
sonicated in a water bath for 10 min, and subjected to centrifuga-
tion at 13,000  g for 20 min at 4 C. The supernatant was trans-
ferred to a new tube, diluted to 10% acetonitrile (v/v), and subjected
to solid phase extraction on an HLB Oasis Cartridge (30 mg, Waters,
Manchester). Following a wash with 40% acetonitrile/0.1% formic
acid (v/v) in water, the analytes were eluted with 70% acetonitrile
(v/v) in water, dried under vacuum, and resuspended in 50 ml of 2%
acetonitrile/0.1% formic acid (v/v) in water. LC-MS/MS was per-
formed on nano-ﬂow LC-Orbitrap as described in detail [20]. To
determine pharmacokinetic parameters, logarithmic linear
regression was used to calculate the slope of the terminal disposi-
tion phase, based onwhich the terminal phase elimination half-life
(t1/2) and the elimination constant (Kel) were determined using a
single compartment model with curve stripping.
2.4. Enzyme assays
Frozen tissue was pulverized into powder under liquid N2.
A
B
TBE-31
Fig. 1. (A) TBE-31 binds to sulfhydryl groups in a Michael addition reaction forming
covalent, but reversible adducts. (B) Pharmacokinetics of TBE-31 in female C57/BL6
mice (n ¼ 3). TBE-31 (10 mmol/kg) was administered by oral gavage. Blood (10 ml) was
drawn from the tail vein at 10, 20, 40, 60 min post-dosing, and subsequently at 2, 4, 6,
8, and 24 h. The blood levels of TBE-31 were determined at each time point using a
stable isotope dilution LC-MS method on nano-ﬂow LC-Orbitrap. Values are
means ± 1 S.E.M.
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Approximately 30 mg of powder were homogenized in an ice bath
in ice-cold buffer [100 mM potassium phosphate, pH 7.4; 100 mM
KCl; 0.1 mM ethylenediaminetetraacetic acid (EDTA)], and sub-
jected to centrifugation at 4 C (15,000 g for 10min). Supernatant
fractions were used to determine the enzyme activities of NAD(P)
H:quinone oxidoreductase 1 (NQO1)withmenadione as a substrate
[21], glutathione S-transferase (GST) with CDNB as a substrate [22],
and the protein concentration using the bicinchoninic acid (BCA)
assay (Thermo Scientiﬁc).
2.5. Blood tests
Blood tests were performed at the Mary Lyon Centre (MRC,
Harwell, UK) on plasma samples free of hemolysis that had been
isolated from mice fed continuously with TBE-31 (27.6 mg of TBE-
31 per kg of food) for 18 days.
2.6. Statistical analysis
Values are means ± 1 S.D. or 1 S.E.M., as indicated in the ﬁgure
legends. The differences between groups were determined by
Students t-test using Excel (Microsoft Corp.).
3. Results and discussion
3.1. Pharmacokinetics and pharmacodynamics of a single dose of
orally administered TBE-31
To determine the blood levels of TBE-31, we employed a quan-
titative liquid chromatography/mass spectrometry-based approach
coupled with the use of a stable isotope-labeled internal standard,
in which both nitrile groups of TBE-31 are labeled with 13C and 15N
atoms, i.e. (±)-[13C215N2]-TBE-31 [20]. The high sensitivity of this
method (which has an estimated on-column limit of detection of
80 fmol) enabled us to examine the pharmacokinetic proﬁle of
orally administered TBE-31 by drawing small amounts (10 ml) of
blood from the mouse tail vein. This allowed us to determine the
blood levels of the compound at 9 different time-points using three
animals per group. Following a single oral dose of 10 mmol/kg, the
concentration of TBE-31 in whole blood exhibited two peaks
(Fig. 1B). The ﬁrst peak was at 22.3 nM 40 min after dosing. After a
rapid decline, a second broader peak was observed at 15.5 nM 4 h
after dosing. The reason for the presence of two peaks is unclear;
however it is noteworthy that sulforaphane, another potent Nrf2
activator, which reacts reversibly with sulfhydryl groups, such as
the cysteine sensors of Keap1 [3,23e25], or reduced glutathione
[26e28] shows a similar pharmacokinetic behavior in Spra-
gueeDawley rats [29], and could be due to accumulation of gluta-
thione conjugates, and their subsequent deconjugation to give the
parent compound.
The area under the concentrationetime curve (AUC) from time
zero to 24 h after dosing was 195.5 h/nmol/l, the terminal phase
elimination half-life (t1/2) was 10.2 h, and the kel was 0.068 h1. As
expected, there was no detectable TBE-31 in blood from vehicle-
treated animals, conﬁrming the absence of any endogenous sour-
ces and the speciﬁcity of the detection method. Importantly, the
TBE-31 concentrations that were detected in the blood of the TBE-
31-treated animals are entirely consistent with the concentrations
of the compound which are typically used in cell culture experi-
ments and have been shown to activate robustly Nrf2 and to protect
against the toxicities of damaging agents, such as peroxynitrite or
the combination of 6-thioguanine and ultraviolet radiation
[15,16,18,30].
To assess the pharmacodynamics of Nrf2 activation by TBE-31,
we determined the activity of NQO1, an enzyme encoded by a
prototypic Nrf2-dependent gene, in liver and heart of the animals.
In comparison with vehicle-treated animals, the speciﬁc enzyme
activity of hepatic NQO1was higher by 2.4-fold (n¼ 3, p¼ 0.00003)
24 h after a single orally administered dose (10 mmol/kg, or ~200
nmol/mouse) of TBE-31 (Fig. 2A). Although to a lower degree,
perhaps reﬂecting the much higher (by ~4-fold) levels of the
enzyme in heart compared to liver, cardiac NQO1 was also induced
and was 1.5-fold higher in TBE-31-treated than in vehicle-treated
animals (n ¼ 3, p ¼ 0.003) (Fig. 2B).
3.2. Pharmacodynamics of chronically administered TBE-31
Due to the reversibility of the reactionwith their protein targets,
reversible covalent drugs do not permanently modify their protein
targets and are suitable for chronic administration. To assess the
pharmacodynamic effects of chronic TBE-31 administration, the
compound was mixed with the diet and the animals were fed with
this diet for 18 days, receiving continuously a daily dose of
~200 nmol TBE-31. In relation to our interest in developing pre-
clinical models of cutaneous carcinogenesis under immunosup-
pressed conditions, during the last two weeks of the experiment,
the mice were also receiving the immunosuppressive agent
azathioprine (10 mg/kg) in the drinking water.
The TBE-31 treatment led to upregulation of the activity of
NQO1 by 3.2-, 1.3-, 1.7-, 3.2- and 3.2-fold in liver, heart, skin, kidney,
Fig. 2. Pharmacodynamics of Nrf2 activation by a single oral dose of TBE-31 in female C57/BL6 mice (n ¼ 3). Speciﬁc enzyme activity of NQO1 in liver (A) and heart (B) 24 h after a
single oral dose (10 mmol/kg) of TBE-31. Values are means ± 1 S.D.
R.V. Kostov et al. / Biochemical and Biophysical Research Communications 465 (2015) 402e407404
and stomach, respectively (n ¼ 6, p < 0.00001) (Fig. 3A). We also
measured the speciﬁc activity of glutathione S-transferase (GST),
another Nrf2-dependent enzyme. Similar to the effect on NQO1,
chronic dietary administration of TBE-31 induced the activity of
GST by 2.6-, 1.4-, 1.4-, 1.9-, and 2.6-fold in liver, heart, skin, kidney,
and stomach, respectively (n ¼ 6, p < 0.00001) (Fig. 3B). The highly
Fig. 3. Continuous feeding with TBE-31 (27.6 mg of TBE-31 per kg of food) for 18 days increases the speciﬁc enzyme activity of NQO1 (menadione as a substrate) (A) and GST (CDNB
as a substrate) (B) in female C57/BL6 mice (n ¼ 6). Values are means ± 1 S.D.
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statistically signiﬁcant induction of both enzymes in all organs
examined demonstrated the pharmacodynamic effects of chronic
TBE-31 administration and further conﬁrmed that TBE-31 is a
potent Nrf2 activator in vivo.
3.3. Toxicity assessment of chronically administered TBE-31
There were no obvious signs of toxicity, as judged by the simi-
larity in body weight (Fig. 4) and behavior between the animals on
the control diet and those receiving continuously a daily dose of
~200 nmol TBE-31 in the diet for 18 days. To further strengthen this
conclusion, we performed a detailed analysis of the plasma levels of
creatinine, alkaline phosphatase (ALP), alanine aminotransferase
(ALT), aspartate aminotransferase (AST), total cholesterol, low-
density lipoproteins (LDL), high-density lipoproteins (HDL), tri-
glycerides, free fatty acids, glucose, bilirubin, and ketone bodies
(Table 1). The activities of ALP, ALT and AST were not signiﬁcantly
different between the two groups, indicating unaltered liver func-
tion and conﬁrming the absence of toxicity by the continuous TBE-
31 treatment. Most of the other evaluated parameters were also
very similar between the groups. There were two exceptions: the
levels of LDL were higher (by 1.3-fold, p < 0.05) in the TBE-31-
treated group compared to the control group, whereas the levels
of bilirubin were lower (by 35%, p < 0.05).
The increase in LDL by the TBE-31 treatment is consistent with
the pro-atherogenic effects of Nrf2 that have been previously
described in apolipoporotein E (ApoE)-deﬁcient mice [31e33].
However, it is not clear at present whether Nrf2 is pro-atherogenic
in man, and perhaps more importantly, whether the pro-
atherogenic role of Nrf2 requires its persistent (rather than tran-
sient) activation. Nonetheless, this result warrants caution when
designing dosing regimens with Nrf2 activators in humans.
The decrease in the levels of bilirubin in the plasma of the TBE-
31-treated animals is in agreement with the role of Nrf2 in regu-
lating the gene expression of microsomal UDP-
glucuronosyltransferases, such as UGT1A1 [34,35], the enzymes
that are principally responsible for the glucuronidation and elimi-
nation of bilirubin [36]. This result suggests that Nrf2 activation by
agents such as TBE-31 could be potentially developed as a thera-
peutic approach for conditions of impaired bilirubin glucur-
onidation, such as CriglereNajjar and Gilbert's syndromes.
Notably, although TBE-31 is largely eliminated by 24 h after
dosing, its cytoprotective effects are evident for much longer pe-
riods of time. This is because the ultimate cytoprotective agents are
not TBE-31, or even Nrf2, but the Nrf2-dependent transcriptional
targets, which are proteins with long half-lives. We have recently
demonstrated that NQO1 is induced to essentially the same extent
at 24- or 72-h after dosing with TBE-31 in the murine skin, where
the half-life of the compound is ~10 h [19]. This long-lasting
pharmacodynamic effect makes the maintenance of steady-state
plasma levels of the inducer unnecessary, allowing for chronic
dosing at a low frequency. In addition, because reversible covalent
binding does not lead to formation of stable adducts with the target
protein, repeated dosing regimens are possible without immuno-
logical consequences. Indeed, chronic (~30 weeks) topical appli-
cation of small quantities (40 nmol per animal) of TBE-31 twice a
week resulted in dramatically reduced tumor multiplicity and
burden in a model of ultraviolet radiation-mediated skin carcino-
genesis in SKH-1 hairless mice receiving azathioprine treatment
[19]. In a rat model of aﬂatoxin-mediated hepatocarcinogenesis,
oral administration of TBE-31, three times per week for three
weeks, essentially abolished the formation of pre-neoplastic foci in
liver [15]. Taken together, these ﬁndings illustrate the advantages of
reversible covalent drugs and especially those whose protein tar-
gets subsequently affect the activity of transcription factors that, in
turn orchestrate the expression of networks of genes, and
encourage future drug development of compounds of this class.
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